CTRI/2022/03/040741已完成未知
A randomized, open label, multi-centre, two-treatment, two-period, two-sequence, two-stage, multiple dose, steady-state, crossover, bioequivalence study of Olaparib tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (olaparib) tablets 150 mg (AstraZeneca Pharmaceuticals LP), in patients with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer under fasting condition.
ek Pharmaceuticals dd0 个研究点目标入组 70 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.First-Line Maintenance Treatment of BRCA mutated Advanced Ovarian Cancer maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. OR Maintenance Treatment of Recurrent Ovarian Cancer maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum based chemotherapy. OR Advanced Germline BRCA mutated Ovarian Cancer After 3 or More Lines of Chemotherapy treatment of adult patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. OR Germline BRCA-mutated HER2 negative Metastatic Breast Cancer treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2 negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
- •2.Non-smoking, non-pregnant, non-lactating female
- •3.patient more than or equal to 18 years of age with a body mass index BMI in the range of 18.50 to 30.00 kg per m2 (both inclusive).
- •4.Able to give written informed consent for participation in the trial and willing to adhere to protocol requirements.
- •5.Patient having an estimated survival of at least 3 months
- •6.Adequate organ and bone marrow function based upon the following laboratory criteria at the time of eligibility assessment prior to dosing in period 1 Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- •7.Women of non child bearing potential with documented evidence of hysterectomy or bilateral salpingectomy or bilateral oophorectomy at least 6 months prior to IMP administration) or postmenopausal for at least 12 consecutive months. OR Women of child bearing potential must have negative pregnancy test at screening visit and before randomization and must agree to use an effective method of avoiding pregnancy (including oral, transdermal or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to IMP administration] sexual partner) for at least 4 weeks prior to IMP administration, during the study and up to 6 months after the last dose of IMP. Cessation of birth control after this point should be discussed with a responsible physician.
排除标准
- •Patients who meet any of the following criteria at screening will not be enrolled in the study:
- •History of known hypersensitivity to olaparib or its
- •components which, in the opinion of the Investigator,
- •would compromise the safety of the patient or the results
- •of the study.
- •- Usage of strong and moderate CYP3A4 inhibitors
- •(e.g., cimetidine, ciprofloxacin, grapefruit juice) or strong
- •and moderate CYP3A4 inducers (e.g., carbamazepine,
- •phenytoin, St. Johnâ??s Wort, rifampicin) within 30 days
- •prior to first dosing in Period 01.
- •- Pregnant or lactating females.
- •- History or presence of clinically significant lactose,
- •galactose, or fructose intolerance.
研究者
相似试验
已完成
1 期
Comparative study of Nilutamide 150 mg tabletCTRI/2018/01/011386Genus Lifesciences Inc40
Unknown
不适用
euprorelin Acetate Injectable Suspension 11.25 mg in male subjects with metastatic prostate cancerCTRI/2019/08/020820Daewoong Pharmaceutical Co Ltd
进行中（未招募）
不适用
Bioequivalence study in advanced renal cell carcinoma patients under fasting condition.CTRI/2022/04/041694Oncogen Pharma Malaysia Sdn Bhd
已完成
4 期
Pharmacokinetic Study of Pazopanib in subjects with Advanced renal cell carcinoma.CTRI/2020/10/028441Torrent Pharmaceuticals Ltd India61
进行中（未招募）
不适用
Bioequivalence study of Olaparib Tablets 150 mg with LYNPARZA�® (Olaparib) tablets 150 mg in male or female patients with ovarian cancer or breast cancer or prostate cancer.CTRI/2021/08/035525atco Pharma Limited